All In Biotech

Drug Trial Radar · NCT05113095

A Survey of Darvadstrocel in People With Crohn's Disease

Postmarketing Surveillance Registry to Evaluate Safety and Efficacy of Darvadstrocel for the Treatment of Complex Perianal Fistulas in Crohn's Disease Patients (J-INSPIRE) (All-case Surveillance)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

275

Planned (sponsor's estimate)

Start

Nov 30, 2021

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 9, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a survey in Japan of Darvadstrocel injection used to treat Crohn's disease people with complicated anal fistula. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Darvadstrocel injection and to check if Darvadstrocel injection improves symptoms of Crohn's disease. During the study, participants with Crohn's disease will take Darvadstrocel injection according to their clinic's standard practice. The study doctors will check for side effects from Darvadstrocel for 36 months.

Conditions

  • Crohn's Disease

Interventions

  • DarvadstrocelBiological

    Darvadstrocel injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: 36 Months
  2. Percentage of Participants who Achieve Clinical ResponseTime frame: Baseline, Up to Months 36
  3. Percentage of Participants who Achieve Clinical RemissionTime frame: Baseline, Up to Months 36
  4. Percentage of Participants who Achieve Combined RemissionTime frame: Baseline, Up to Months 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Takeda Selected Site

    Tokyo, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.